{"doi":"10.1371/journal.pone.0264674","title":"Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy","abstract":"Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. We analyzed dendritic cells in 15 pediatric subjects (5-12 years) undergoing a phase 1 single-center POIT study. We examined dendritic cells at baseline, 6-, 12-, 18- and 24-weeks after initiation of POIT and responders of therapy were compared to non-responders and healthy controls. The distribution frequency of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) from peripheral blood samples were measured in vitro. A general linear mixed model was used, and included fixed effects for cohort (responder, non-responder, or healthy control), time (0-, 6-, 12-, 18-, and 24-weeks), and the cohort-time interaction term. P-values were adjusted for multiple hypothesis testing using Tukey's method. We observed that POIT responders had reduced TNFa producing myeloid dendritic cells (mDCs) compared to non-responders. Additionally, non-responders had increased OX40L expressing mDCs at 18-weeks compared to responders. In conclusion, our findings suggest that a reduced pro-inflammatory phenotype in DCs could potentially serve as a predictor of early outcome and success of POIT desensitization.","journal":"PLoS ONE","year":2022,"id":282319,"datarank":0.3905510486192018,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.07863481736722638,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.07863481736722638,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":7,"citers_with_citation_signal":6,"citers_with_endowment":6,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9547,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":724528,"name":"Levi B. Watkin","orcid":"0000-0003-0404-4548","position":1,"is_corresponding":false},{"id":232649,"name":"Charles G. Minard","orcid":"0000-0003-4631-6943","position":2,"is_corresponding":false},{"id":724529,"name":"Kimberly Schuster","orcid":"0000-0002-2352-438X","position":3,"is_corresponding":false},{"id":725180,"name":"Oluwatomi Hassan","orcid":null,"position":4,"is_corresponding":false},{"id":935882,"name":"Aikaterini Anagnostou","orcid":"0000-0001-6240-7437","position":5,"is_corresponding":false},{"id":265886,"name":"Jordan S. Orange","orcid":"0000-0001-7117-7725","position":6,"is_corresponding":false},{"id":325692,"name":"David B. Corry","orcid":"0000-0001-9729-1016","position":7,"is_corresponding":false},{"id":273994,"name":"Carla M. Davis","orcid":"0000-0003-0866-7822","position":8,"is_corresponding":false},{"id":527403,"name":"Sara Anvari","orcid":"0000-0002-9942-6188","position":0,"is_corresponding":true}],"reference_count":9,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:29:15.734856Z","pmid":"35617270","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}